Ratings Lunit Inc.

Equities

A328130

KR7328130000

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
55,800 ^KRW	-0.89%		-0.71%	-31.87%

May. 03	Volpara to Delist After Court Approves Acquisition by Lunit	MT
Apr. 16	Lunit Wins Shareholder Approval for Volpara Health Takeover	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
LUNIT INC.	-31.87%	1.17B		-
VEEVA SYSTEMS INC.	+5.85%	32.93B		C
PRO MEDICUS LIMITED	+20.16%	7.94B		C-
SECTRA AB	+30.81%	4.19B		B-
EVOLENT HEALTH, INC.	-25.95%	2.8B		C-
OMNICELL, INC.	-19.96%	1.38B		B
SIMULATIONS PLUS, INC.	+8.02%	966M		C
B-SOFT CO.,LTD.	-35.73%	900M		-
VERADIGM INC.	-25.74%	839M	-	C+
SURGICAL SCIENCE SWEDEN AB	-20.05%	687M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes